BioTuesdays Feature Articles | Life Sciences News

Feature

Vital Therapies pivotal ELAD trial to read out at end of third quarter

By Len Zehrs Vital Therapies (NASDAQ:VTL) expects to report top line data from its ELAD pivotal study, known as VTL-308, in patients with severe alcoholic hepatitis (sAH), an acute form of liver failure, by the end of...

March 20, 2018

Feature

DarioHealth simplifies diabetes with managed care platform

By Len Zehrs DarioHealth’s (NASDAQ:DRIO) diabetes managed care platform covers all facets of the disease, with a blood glucose device coupled directly to a patient’s smartphone to provide 100% data...

March 13, 2018

Feature

liberDi readies first-in-man study of portable dialysis system

By Len Zehrs Closely-held liberDi plans to initiate in the first half of 2018 the first-in-man clinical trial of its Smart Peritoneal Dialysis System, a small, portable and automatic dialysis device, which is designed...

March 6, 2018

Feature

Scientus Pharma considering go-public transaction on heels of financing

By Len Zehrs Closely-held Scientus Pharma hopes to go public in mid-year, possibly through a reverse takeover of a publicly traded shell company, following a successful $15.8-million private equity financing, which...

February 27, 2018

Feature

3DS Telo-HL test aims to personalize cancer treatment

By Len Zehrs 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) has reported positive results from a preliminary analysis of trial data for Telo-HL, its test for Hodgkin’s lymphoma (HL) that is designed to personalize...

February 20, 2018

Feature

Eiger BioPharma has multiple catalysts in orphan diseases in 2018

By Len Zehrs Despite a failed Phase 2 trial in pulmonary arterial hypertension (PAH), Eiger BioPharmaceuticals (NASDAQ:EIGR) still has multiple shots on goal with its targeted therapies for orphan diseases, including a...

February 6, 2018

Feature

Spartan Bioscience takes aim at Legionnaires’ disease

By Len Zehrs Closely-held Spartan Bioscience’s recently launched an on-site rapid DNA test for Legionnaires’ disease that has the potential to eliminate lengthy culture testing in third-party labs and detect the...

January 30, 2018

Feature

FDA advisory vote on TLANDO not a knockout for Lipocine

By Len Zehrs Although Lipocine (NASDAQ:LPCN) is disappointed by a FDA advisory committee vote against the benefit/risk profile of TLANDO, its oral testosterone replacement therapy (TRT), the company believes there is...

January 23, 2018

Feature

Chi-Med transforming into fully integrated pharma

By Len Zehrs After 17 years of blistering growth in China, Hutchison China Meditech (Chi-Med) (AIM, NASDAQ:HCM) is taking center stage as a global drug innovator, with a fully integrated pipeline approaching regulatory...

January 9, 2018

Feature

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

By Len Zehrs Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have...

December 12, 2017

Feature

Crescita targeting $50-million in revenue in 5 years

By Len Zehrs Crescita Therapeutics (TSX:CTX), is aiming to be a $50-million commercial dermatology company in the next five years, with a portfolio of non-prescription skincare products and prescription drug products...

December 5, 2017

Feature

BioLight dry eye subsidiary approaching CE Mark filing, U.S. pivotal trial

By Len Zehrs DiagnosTear, the dry eye diagnostic subsidiary of BioLight Life Sciences (TASE:BOLT), hopes to file by the end of 2017 for CE Mark approval in Europe and begin a pivotal trial in the U.S. in mid-2018 with...

November 28, 2017

Feature

GeNeuro pioneering HERVs against neurodegenerative and autoimmune diseases

By Len Zehrs Swiss-based GeNeuro (Euronext Paris: CH0308403085 – GNRO) is leveraging the biology of human endogenous retroviruses (HERVs) to stop the causes of neurodegenerative and autoimmune diseases, such as multiple...

November 21, 2017

Feature

Marrone Bio focused on 2 near-term pest management products

By Len Zehrs Marrone Bio Innovations (NASDAQ:MBII), which recently received EPA approval for its newest biological fungicide, Stargus, is focused on commercializing its two near-term products: a new herbicide for...

November 14, 2017

Feature

Mazor’s odyssey to spine robotic surgery leader

By Len Zehr Since its founding 15 years ago, Mazor Robotics (NASDAQ, TASE:MZOR) has overcome challenges typical to medical device startups to become the leader and possibly the standard of care in spine robotics surgery...

October 31, 2017

Feature

Flex Pharma focused on 3 clinical readouts in 2018

By Len Zehr Flex Pharma (NASDAQ:FLKS) expects to report clinical readouts in 2018 from three Phase 2 studies of its anti-cramping drug candidate, FLX-787, in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth...

October 24, 2017

Feature

Thera sees ibalizumab as company game changer

By Len Zehr If approved by the FDA in the next few months, ibalizumab for patients with multidrug resistant HIV has the potential to be a game changer for Theratechnologies (TSX:TH). The FDA accepted ibalizumab for...

October 17, 2017

Feature

Titan’s next ProNeura implant could be game changer in PD

By Len Zehr After gaining widespread attention with its FDA-approved Probuphine implant for the maintenance treatment of opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is setting out to develop an implant to...

October 10, 2017

Feature

Diffusion Pharma readies pivotal hypoxic GBM trial

By Len Zehr Diffusion Pharmaceuticals (NASDAQ:DFFN) expects to begin before the end of 2017 a pivotal clinical trial with its trans sodium crocetinate (TSC) lead compound to re-oxygenate oxygen-deprived tissue in...

October 3, 2017

Feature

In conversation with Hrishikesh Suresh of NeuroGate

By Len Zehr As CEO and one of three co-founders of upstart NeuroGate, Hrishikesh Suresh currently is completing his final year as a medical student at McMaster University in Hamilton, Ontario and plans to pursue a six...

September 26, 2017

Feature

American CryoStem pioneering adipose tissue stem cell technologies

By Len Zehr American CryoStem (OTC:CRYO) has developed platform technologies dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue and adipose derived stem cells (ADSCs)...

September 19, 2017

Feature

BiondVax to start pivotal universal flu vaccine trial next year

By Len Zehr BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) expects to be Phase 3 ready in 2018 to begin pivotal testing in Europe of a universal flu vaccine with the potential to provide multi-season and multi-strain...

September 12, 2017

Subscribe